Tags

Type your tag names separated by a space and hit enter

Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma.
Cancer. 2004 May 15; 100(10):2139-47.C

Abstract

BACKGROUND

The granulin-epithelin precursor (GEP) was preferentially expressed in invasive ovarian tumor epithelium specimens compared with specimens of borderline ovarian tumors. The objective of the current study was to evaluate the anatomic site-related and cellular expression of GEP and its association with clinicopathologic parameters and survival in patients with advanced-stage ovarian carcinoma.

METHODS

Effusions (n = 190), corresponding primary tumor specimens (n = 64), and specimens of metastatic lesions (n = 125) were analyzed using immunohistochemistry with a specific polyclonal antipeptide antibody. In addition, 36 effusions were analyzed using immunoblotting.

RESULTS

GEP was detected in tumor cells in 171 of 190 (90%) effusions and demonstrated both focal membrane and cytoplasmic localization. Mesothelial cells were often GEP positive (81%). GEP was found in carcinoma cells in 180 of 189 (95%) tumor biopsy specimens, with stromal and endothelial cell expression in 93 of 180 (52%) and 124 of 185 (67%) specimens, respectively. Lower GEP expression in stromal cells was observed in metastases sampled during or after chemotherapy (P = 0.034). The presence of GEP-positive stromal cells in untreated primary tumor specimens correlated with worse overall survival (P = 0.014). Significantly more frequent GEP expression was observed in tumor cells of both primary (P = 0.002) and metastatic (P < 0.001) tissue specimens compared with malignant effusions.

CONCLUSIONS

GEP expression was observed in primary and metastatic epithelial ovarian carcinoma specimens, with down-regulated expression in tumor cells of malignant effusions. The poor outcome associated with stromal GEP expression suggests a prognostic role for this growth factor in ovarian carcinoma.

Authors+Show Affiliations

Molecular Signaling Section, Laboratory of Pathology, Center for Cancer Research, The National Cancer Institute, Bethesda, Maryland 20892, USA. davidsob@mail.nih.govNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15139056

Citation

Davidson, Ben, et al. "Granulin-epithelin Precursor Is a Novel Prognostic Marker in Epithelial Ovarian Carcinoma." Cancer, vol. 100, no. 10, 2004, pp. 2139-47.
Davidson B, Alejandro E, Flørenes VA, et al. Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer. 2004;100(10):2139-47.
Davidson, B., Alejandro, E., Flørenes, V. A., Goderstad, J. M., Risberg, B., Kristensen, G. B., Trope, C. G., & Kohn, E. C. (2004). Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer, 100(10), 2139-47.
Davidson B, et al. Granulin-epithelin Precursor Is a Novel Prognostic Marker in Epithelial Ovarian Carcinoma. Cancer. 2004 May 15;100(10):2139-47. PubMed PMID: 15139056.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. AU - Davidson,Ben, AU - Alejandro,Emilyn, AU - Flørenes,Vivi Ann, AU - Goderstad,Jeanne-Mette, AU - Risberg,Björn, AU - Kristensen,Gunnar B, AU - Trope,Claes G, AU - Kohn,Elise C, PY - 2004/5/13/pubmed PY - 2004/6/2/medline PY - 2004/5/13/entrez SP - 2139 EP - 47 JF - Cancer JO - Cancer VL - 100 IS - 10 N2 - BACKGROUND: The granulin-epithelin precursor (GEP) was preferentially expressed in invasive ovarian tumor epithelium specimens compared with specimens of borderline ovarian tumors. The objective of the current study was to evaluate the anatomic site-related and cellular expression of GEP and its association with clinicopathologic parameters and survival in patients with advanced-stage ovarian carcinoma. METHODS: Effusions (n = 190), corresponding primary tumor specimens (n = 64), and specimens of metastatic lesions (n = 125) were analyzed using immunohistochemistry with a specific polyclonal antipeptide antibody. In addition, 36 effusions were analyzed using immunoblotting. RESULTS: GEP was detected in tumor cells in 171 of 190 (90%) effusions and demonstrated both focal membrane and cytoplasmic localization. Mesothelial cells were often GEP positive (81%). GEP was found in carcinoma cells in 180 of 189 (95%) tumor biopsy specimens, with stromal and endothelial cell expression in 93 of 180 (52%) and 124 of 185 (67%) specimens, respectively. Lower GEP expression in stromal cells was observed in metastases sampled during or after chemotherapy (P = 0.034). The presence of GEP-positive stromal cells in untreated primary tumor specimens correlated with worse overall survival (P = 0.014). Significantly more frequent GEP expression was observed in tumor cells of both primary (P = 0.002) and metastatic (P < 0.001) tissue specimens compared with malignant effusions. CONCLUSIONS: GEP expression was observed in primary and metastatic epithelial ovarian carcinoma specimens, with down-regulated expression in tumor cells of malignant effusions. The poor outcome associated with stromal GEP expression suggests a prognostic role for this growth factor in ovarian carcinoma. SN - 0008-543X UR - https://www.unboundmedicine.com/medline/citation/15139056/Granulin_epithelin_precursor_is_a_novel_prognostic_marker_in_epithelial_ovarian_carcinoma_ L2 - https://doi.org/10.1002/cncr.20219 DB - PRIME DP - Unbound Medicine ER -